We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03608033
Recruitment Status : Recruiting
First Posted : July 31, 2018
Last Update Posted : May 30, 2019
Sponsor:
Information provided by (Responsible Party):
Omeros Corporation

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of OMS721 in patients with IgA nephropathy. The study will assess proteinuria by 24-hour urine protein excretion (UPE) in g/day at 36 weeks from beginning of treatment.

Condition or disease Intervention/treatment Phase
IgA Nephropathy Biological: OMS721 Other: Vehicle (D5W or saline) Phase 3

Detailed Description:

This is a Phase 3, double-blind, randomized, placebo-controlled, study in patients aged 18 years and above with a biopsy-confirmed diagnosis of IgAN and with 24-hour UPE that is > 1 g/day within 6 months prior to Screening or uPCR > 0.75 by spot urine at Screening. During the study, all patients will continue optimized renin-angiotensin system (RAS) blockade. The study consists of five periods: Screening, Run-In, Initial Treatment (Weeks 1-12), Response Evaluation (Weeks 13-36), and Follow-Up (Weeks 37-144). Patients are assessed for re-treatment based on their response to 24-hour UPE. Additional treatment may be given to patients whose 24-hour UPE is > 1 g/day following the Initial Treatment Period and who relapse during the Response Evaluation and Follow-Up periods. Patients may be qualified for Open-Label Treatment with OMS721 after Week 72.

Approximately 450 patients are to enrolled in two groups of 225 patients per arm.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 450 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Eligible patients will be randomized 1:1 to receive OMS721 or placebo
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)
Actual Study Start Date : February 16, 2018
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : April 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: OMS721
Administration of OMS721
 Biological: OMS721
Biological: OMS721
Placebo Comparator: Placebo
Administration of Vehicle (D5W or Saline Solution)
 Other: Vehicle (D5W or saline)
5% Dextrose in water or normal saline solution


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change from baseline in 24-hour urine protein excretion (UPE) in g/day at 36 weeks from beginning of treatment [ Time Frame: 36 Weeks ]

Secondary Outcome Measures :
  1. Number of patients with treatment related Adverse Events as assessed by CTCAE v 4.0 [ Time Frame: 168 Weeks ]
  2. Change from baseline in renal function as determined by the rate of change in estimated glomerular filtration rate (eGFR) up to 144 weeks from beginning of treatment [ Time Frame: 144 Weeks ]
  3. Change from baseline in 24-hour urine protein excretion (UPE) in g/day at 36 weeks from beginning of treatment in the subset of patients with baseline high proteinuria (defined as 24-hour UPE ≥ 2 g/day) [ Time Frame: 36 Weeks ]
  4. Time-averaged change in urine protein/creatinine ratio (uPCR) through 36 weeks. [ Time Frame: 36 Weeks ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 years or older at the onset of Screening
  • Biopsy confirmed diagnosis of IgAN within 8 years prior to Screening
  • Proteinuria of > 1 g/day within 6 months prior to Screening or uPCR > 0.75 by spot urine at Screening
  • Mean of two proteinuria measurements > 1 g/day at baseline
  • Estimated glomerular filtration rate of ≥ 30 mL/min/1.73 m2 at Screening and baseline

Exclusion Criteria:

  • Treatment with immunosuppressants (e.g., azathioprine or cyclophosphamide), or cytotoxic drugs, for IgA within 8 weeks prior to Screening. Treatment with immunosuppressants or cytotoxic drugs for IgAN is not allowed during the Run-In Period. Treatment with immunosuppressants are allowed if such treatment is for indications other than IgAN.
  • Treatment with eculizumab within 8 weeks prior to Screening. Treatment with eculizumab is not allowed during the Run-In Period.
  • Treatment with systemic corticosteroids within 8 weeks prior to Screening. Treatment with systemic corticosteroids is not allowed during the Run-In Period.
  • Uncontrolled BP, a systolic BP of > 150 mmHg and a diastolic BP of > 100 mmHg at rest despite the combination of two or more anti-hypertensives including ACEIs, ARBs, or direct renin inhibitors at Screening and baseline
  • Female patients who are pregnant, breast feeding, or planning to become pregnant up through 12 weeks after the last dose of study drug, including possible retreatments
  • Clinical or biological evidence of Type 1 diabetes mellitus (DM), or poorly controlled DM with hemoglobin A1c > 7.5 or with evidence of diabetic nephropathy on biopsy, systemic lupus erythematosus, IgA vasculitis (Henoch-Schonlein purpura), secondary IgAN, or other renal disease during Screening and Run-In
  • History of renal transplantation
  • Have a known hypersensitivity to any constituent of the investigational product
  • Rapidly progressive glomerulonephritis
  • Significant abnormalities in clinical laboratory values
  • History of human immunodeficiency virus (HIV), evidence of immune suppression, active HCV infection (patients with positive anti-HCV antibody but a non-detected HCV RNA PCR can enroll), HBV infection (patients with positive HBsAg are excluded. For patients with isolated positive anti-HBc antibody, HBV DNA test by PCR must be non-detectable to enroll).
  • Diagnosis of a malignancy except for adequately treated and cured basal or squamous cell skin cancer, curatively treated in situ disease, or other cancer from which the patient has been disease-free for ≥ 5 years
  • Have received any other investigational drug or device or experimental procedures within 30 days of the Screening Visit (SV)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03608033


Contacts
Layout table for location contacts
Contact: Laura Haas (206) 676-0886 lhaas@omeros.com
Contact: Fay Wang (206) 676-0863 fwang@omeros.com

Locations
Layout table for location information
United States, Alabama
Omeros Investigational Site Recruiting
Florence, Alabama, United States, 35630
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
United States, Arizona
Omeros Investigational Site Recruiting
Mesa, Arizona, United States, 85210
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
United States, California
Omeros Investigational Site Recruiting
Los Angeles, California, United States, 90022
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
Omeros Investigational Site Recruiting
Stanford, California, United States, 94305
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
United States, Florida
Omeros Investigational Site Recruiting
Miami, Florida, United States, 33136
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
United States, Georgia
Omeros Investigational Site Recruiting
Lawrenceville, Georgia, United States, 30046
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
United States, Illinois
Omeros Investigational Site Recruiting
Crystal Lake, Illinois, United States, 60012
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
United States, Iowa
Omeros Investigational Site Recruiting
Iowa City, Iowa, United States, 52242
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
United States, Massachusetts
Omeros Investigational Site Recruiting
Boston, Massachusetts, United States, 02111
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
United States, Minnesota
University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55414
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
United States, Missouri
Omeros Investigational Site Recruiting
Kansas City, Missouri, United States, 64111
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
United States, New Mexico
Omeros Investigational Site Recruiting
Albuquerque, New Mexico, United States, 87131
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
United States, New York
Omeros Investigational Site Recruiting
New York, New York, United States, 10029
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
United States, Ohio
Omeros Investigational Site Recruiting
Columbus, Ohio, United States, 43210
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
United States, Pennsylvania
Omeros Investigational Site Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
United States, Tennessee
Omeros Investigational Site Recruiting
Nashville, Tennessee, United States, 37232
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
United States, Texas
Omeros Investigational Site Recruiting
Houston, Texas, United States, 77024
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
Omeros Investigational Site Recruiting
San Antonio, Texas, United States, 78215
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
United States, Utah
Omeros Investigational Site Recruiting
Saint George, Utah, United States, 84790
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
United States, Washington
Omeros Investigational Site Recruiting
Seattle, Washington, United States, 98104
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
United States, Wisconsin
Omeros Investigational Site Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
Australia, South Australia
Omeros Investigational Site Recruiting
Adelaide, South Australia, Australia, 5000
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
Austria
Omeros Investigational Site Recruiting
Vienna, Austria, 1220
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
Belgium
Omeros Investigational Site Recruiting
Liège, Liege, Belgium, 4000
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
Bulgaria
Omeros Investigational Site Recruiting
Sofia, Bulgaria, 1431
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
Hungary
Omeros Investigational Site Recruiting
Budapest, Hungary, H-1097
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
Lithuania
Omeros Investigational Site Recruiting
Vilnius, Lithuania, LT-08661
Contact: Laura Haas    (206) 676-0886    lhaas@omeros.com   
Poland
Omeros Investigational Site Recruiting
Warszawa, Poland, 04-749
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
Slovakia
Omeros Investigational Site Recruiting
Banská Bystrica, Slovakia, 975-17
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
Spain
Omeros Investigational Site Recruiting
Madrid, Spain, 28702
Contact: Laura Haas    206-676-0886    lhaas@omeros.com   
Sponsors and Collaborators
Omeros Corporation
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Omeros Corporation
ClinicalTrials.gov Identifier: NCT03608033    
Other Study ID Numbers: OMS721-IGA-001
First Posted: July 31, 2018    Key Record Dates
Last Update Posted: May 30, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Glomerulonephritis, IGA
Urologic Diseases
Glomerulonephritis
 Nephritis
Autoimmune Diseases
Immune System Diseases